Visit CONTRACT PHARMA at Booth 1163

Emergent Appoints Key Executives

04.05.18

Robert G. Kramer Sr. will serve as president and COO, and Richard S. Lindahl will serve as EVP and CFO

Emergent BioSolutions announced executive management changes that continue to align its organizational structure and long-term growth objectives. The company’s board of directors promoted Robert G. Kramer Sr. to the newly-created position of president and chief operating officer, and appointed Richard S. Lindahl as the company’s new executive vice president and chief financial officer.

 

As president and chief operating officer, Kramer will have responsibility for the company's day-to-day operations and the successful execution of the company’s stated growth plan. He will report directly to the company’s chief executive officer, Daniel J. Abdun-Nabi. Kramer joined the company in early 1999 shortly after its founding. Over the years, he has held a variety of executive level positions, including president of Emergent’s Lansing, Michigan manufacturing site and, most recently, executive vice president, administration and chief financial officer.

 

Lindahl joins the company with responsibility for financial operations, investor relations, and information technology. He will also report to Abdun-Nabi. Lindahl most recently served as chief financial officer at CEB Inc.

 

“These management changes enhance the company’s ability to execute on its overall strategy by ensuring an aligned and scalable organizational structure and a strong and deep leadership bench to drive future growth,” said Abdun-Nabi. “The board and I have long valued Bob’s leadership and extensive company knowledge, which position him well in his new role of overseeing our global operations. Bob’s sound business acumen, strategic thinking, and focus on financial discipline have contributed to the company’s growth over the years. Additionally, we are pleased to welcome Rich to the Emergent team. With more than 20 years serving in finance leadership roles in large, growth-oriented public companies, we are confident in the wealth of experience he brings at this important stage in our company’s growth.”

 

“I am grateful for the trust placed in me with the increased scope of responsibility, allowing me to continue to make a meaningful impact on Emergent’s success,” said Kramer. “I look forward to working closely with our seasoned leadership team, further strengthened by the addition of Rich. It is an exciting time to be part of Emergent as we accelerate our growth while meeting the needs of patients and customers in the global public health threats market.”

 

“Emergent’s compelling growth strategy, high quality leadership team, unique assets, and proven execution capabilities make this role a really exciting opportunity for me,” said Lindahl. “I look forward to working closely with my new colleagues and adding value not only to achieve our business objectives, but also to advance the company mission – to protect and enhance life.”